Articles with "biological targeted" as a keyword



What’s new and what’s next for biological and targeted synthetic treatments in psoriatic arthritis?

Sign Up to like & get
recommendations!
Published in 2022 at "Expert Opinion on Biological Therapy"

DOI: 10.1080/14712598.2022.2152321

Abstract: ABSTRACT Introduction Psoriatic arthritis (PsA) is a chronic arthritis typically associated with cutaneous psoriasis (PsO). Its pathogenesis is connected to an innate and acquired immune response, as well as genetic risk alleles. The extent of… read more here.

Keywords: next biological; psoriatic arthritis; biological targeted; targeted synthetic ... See more keywords

Advances in biological and targeted therapies for systemic sclerosis

Sign Up to like & get
recommendations!
Published in 2023 at "Expert Opinion on Biological Therapy"

DOI: 10.1080/14712598.2023.2196009

Abstract: ABSTRACT Introduction Systemic sclerosis (SSc) is a severe, and often life-threatening, autoimmune disease, which causes inflammation and fibrosis of the skin and internal organs. There are currently limited effective therapeutic options for patients with SSc.… read more here.

Keywords: systemic sclerosis; advances biological; ssc; biological targeted ... See more keywords

Risk of hospitalized infections in older elderly patients with rheumatoid arthritis treated with tocilizumab or other biological/targeted synthetic disease-modifying antirheumatic drugs: Evaluation of data from a Japanese claims database.

Sign Up to like & get
recommendations!
Published in 2023 at "Modern rheumatology"

DOI: 10.1093/mr/road031

Abstract: OBJECTIVE We compared the incidence rates of hospitalized infections (HIs) between tocilizumab (TCZ) and other biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in adults aged ≥75 years with rheumatoid arthritis (RA). METHODS We used a Japanese claims… read more here.

Keywords: synthetic disease; risk; hospitalized infections; biological targeted ... See more keywords

Comparative effects of biological and targeted synthetic DMARDs on incident chronic kidney disease in patients with rheumatoid arthritis.

Sign Up to like & get
recommendations!
Published in 2024 at "Rheumatology"

DOI: 10.1093/rheumatology/keae603

Abstract: OBJECTIVES The impact of individual biological/targeted synthetic disease-modifying anti-rheumatic drug (b/tsDMARD) on kidney function in patients with rheumatoid arthritis (RA) remains unclear. This study aimed to determine the comparative effects of b/tsDMARDs on chronic kidney… read more here.

Keywords: disease; biological targeted; patients rheumatoid; group ... See more keywords